Lung cancer metabolomic data from tumor core biopsies enables risk-score calculation for progression-free and overall survival.

Hunter A MillerShesh N RaiXinmin YinXiang ZhangJason A ChesneyVictor H van BerkelHermann B Frieboes

Published in: Metabolomics : Official journal of the Metabolomic Society (2022)

Metabolomic analysis of lung tumor core biopsies has the potential to differentiate patients into low- and high-risk groups based on OS and PFS events and probability.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
ultrasound guided
electronic health record
free survival
data analysis